Intangible Assets (Narrative) (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Feb. 14, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Aug. 23, 2021 |
|
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Impairment of intangible assets | $ 565,000 | $ 565,000 | $ 0 | |||
| Impairment of intangible assets | $ 25,000 | |||||
| Amortization of Intangible Assets | $ 49,000 | $ 123,000 | 116,000 | $ 211,000 | ||
| Patents and Licenses [Member] | ||||||
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Amortization of Intangible Assets | 47,000 | |||||
| Intellectual Property [Member] | ||||||
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Amortization of Intangible Assets | $ 69,000 | |||||
| RubrYc Therapeutics, Inc. [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | ||||||
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Investment | $ 7,500,000 | |||||